Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
OBJECTIVE
The purpose of cancer staging systems is to accurately predict patient prognosis. The outcome of advanced hepatocellular carcinoma (HCC) depends on both the cancer stage and the extent of liver dysfunction. Many staging systems that include both aspects have been developed. It remains unknown, however, which of these systems is optimal for predicting patient survival.


METHODS
Patients with advanced HCC treated over a 5-year period at Memorial Sloan-Kettering Cancer Center were identified from an electronic medical record database. Patients with sufficient data for utilization in all staging systems were included. TNM sixth edition, Okuda, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Chinese University Prognostic Index (CUPI), Japan Integrated Staging (JIS), and Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (GETCH) systems were ranked on the basis of their accuracy at predicting survival by using concordance index (c-index). Other independent prognostic variables were also identified.


RESULTS
Overall, 187 eligible patients were identified and were staged by using the seven staging systems. CLIP, CUPI, and GETCH were the three top-ranking staging systems. BCLC and TNM sixth edition lacked any meaningful prognostic discrimination. Performance status, AST, abdominal pain, and esophageal varices improved the discriminatory ability of CLIP.


CONCLUSIONS
In our selected patient population, CLIP, CUPI, and GETCH were the most informative staging systems in predicting survival in patients with advanced HCC. Prospective validation is required to determine if they can be accurately used to stratify patients in clinical trials and to direct the appropriate need for systemic therapy versus best supportive care. BCLC and TNM sixth edition were not helpful in predicting survival outcome, and their use is not supported by our data.
Huitzil-Melendez
Fidel-David
FD
Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Capanu
Marinela
M
O'Reilly
Eileen M
EM
Duffy
Austin
A
Gansukh
Bolorsukh
B
Saltz
Leonard L
LL
Abou-Alfa
Ghassan K
GK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
J Am Coll Surg. 2006 Oct;203(4):426-35
17000385
Hepatology. 2005 Apr;41(4):707-16
15795889
Eur J Cancer. 1996 Jun;32A(7):1135-41
8758243
Semin Liver Dis. 1999;19(3):329-38
10518312
Cancer. 2002 Mar 15;94(6):1760-9
11920539
J Hepatol. 2004 Jan;40(1):124-31
14672623
Hepatology. 2004 Dec;40(6):1396-405
15565571
Cancer. 2006 May 15;106(10):2181-9
16596622
J Natl Cancer Inst. 2008 May 21;100(10):698-711
18477802
Hepatology. 2000 Apr;31(4):840-5
10733537
J Hepatol. 2001 Sep;35(3):421-30
11592607
J Am Coll Surg. 2003 Nov;197(5):753-8
14585409
Hepatology. 1998 Sep;28(3):751-5
9731568
Am J Gastroenterol. 2008 Mar;103(3):597-604
17970836
J Gastroenterol. 2003;38(3):207-15
12673442
Semin Oncol. 2006 Dec;33(6 Suppl 11):S79-83
17178294
J Hepatol. 2006 Apr;44(4):723-31
16488051
Ann Oncol. 2008 Jun;19(6):1117-26
18303031
Arch Intern Med. 2003 Jan 27;163(2):218-24
12546613
J Natl Compr Canc Netw. 2009 Apr;7(4):397-403
19406040
Hepatogastroenterology. 2007 Jul-Aug;54(77):1534-8
17708292
Gut. 2005 Mar;54(3):411-8
15710992
J Hepatol. 1999 Jul;31(1):133-41
10424293
Dig Dis Sci. 1999 Jun;44(6):1249-53
10389705
Cancer. 1985 Aug 15;56(4):918-28
2990661